DURATION. Started 2020 - ongoing. COLLABORATORS. Australasian Kidney Trials Network, Waitemata District Health Board (New Zealand), Northern Care Alliance NHS Trust (United Kingdom).
Research Themes. Oncology: treatment tolerability, toxicity, adverse events, decision making. Qualifications. ... She also believes that to understand and communicate tolerability we need to incorporate the patient’s voice and experience, utilizing
Before joining the CTC, Nipun worked at the University of Liverpool in the UK as a Research Associate in designing and implementing a community based mental health intervention for older adults
Our People ». RESEARCH AREAS. Specialist Areas. News ». Working at the CTC ». Learning with the CTC ». Password Recovery. To recover your password please fill in your email address. Email. Submit. Don't Have An Account Yet? Create An Account.
An active member of the Statistical Society of Australia, Chris's main statistical research interests are in areas of trial design, randomisation methods, time to event and interim analyses.
Our People ». RESEARCH AREAS. Specialist Areas. News ». Working at the CTC ». Learning with the CTC ». Password Recovery. To recover your password please fill in your email address. Email. Submit. Don't Have An Account Yet? Create An Account.
Both healthcare professionals and health economists are increasingly talking about the importance of including carbon emissions in their decision making. ... entitled “Incorporating carbon into health care: adding carbon emissions to health technology
Our People ». RESEARCH AREAS. Specialist Areas. News ». Working at the CTC ». Learning with the CTC ». Password Recovery. To recover your password please fill in your email address. Email. Submit. Don't Have An Account Yet? Create An Account.
Our People ». RESEARCH AREAS. Specialist Areas. News ». Working at the CTC ». Learning with the CTC ». Password Recovery. To recover your password please fill in your email address. Email. Submit. Don't Have An Account Yet? Create An Account.
However, as previously reported, LuPSMa showed lower adverse events, higher response rates, and improved patient-reported outcomes when compared to cabazitaxel.